Testosterone Replacement Therapy Settlement
$290 Million Drug Injury Settlement
In two separate jury trials, plaintiffs won a total of $290 million in damages in testosterone drug injury lawsuits against AndroGel manufacturer, AbbVie. Plaintiffs claimed use of the testosterone replacement therapy medication resulted in serious cardiovascular injuries. Manufacturers were also accused of inappropriately marketing testosterone medications for symptoms of “low-T” related to normal aging.
In May of 2018, the $150 million verdict was reduced in a second trial after the initial verdict was overturned but the company moved forward with a tentative agreement to settle 4,200 AndroGel drug injury lawsuits for an undisclosed amount. Separately, in 2017 Eli Lilly had agreed to settle 400 federal Axiron lawsuits and Endo International, along with GlaxoSmithKline agreed to settle 1,300 testosterone lawsuits for an estimated $200 million.
Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.